-+ 0.00%
-+ 0.00%
-+ 0.00%

JP Morgan Maintains Overweight on Recursion Pharmaceuticals, Lowers Price Target to $7

Benzinga·11/16/2026 18:34:04
Diffusion vocale
JP Morgan analyst Priyanka Grover maintains Recursion Pharmaceuticals (NASDAQ:RXRX) with a Overweight and lowers the price target from $10 to $7.